Edgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure Drug
MT newswire2026/10/08 12:5208:52 AM EDT, 10/08/2026 (MT Newswires) -- Edgewise Therapeutics (EWTX) dosed the first patient in a phase 2 clinical trial evaluating its investigational oral drug EDG-15400 to treat adults with symptomatic heart failure with preserved ejection fraction, the company said Thursday. The specific indication is for patients who have left ventricular ejection fraction of at least 50%, the company said. The treatment is intended to alleviate impaired cardiac relaxation, a defining feature of the condition that contributes to symptoms and disease impact, the company said. The trial is expected to enroll around 90 patients between 30 and 84 years old with the condition and last 12 weeks, the company said. Shares of Edgewise Therapeutics were up more than 1% in recent premarket activity Thursday.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
